Core Insights - Samsung Epis Holdings is entering a significant phase in 2026, announcing six new candidates in its biosimilar pipeline, aiming for a total of 20 biosimilars by 2030 [1][4] - The company has received IND clearance for its first novel therapeutic candidate, SBE303, and plans to advance its clinical program this year [1][4] - Samsung Bioepis is expanding its portfolio beyond biosimilars, focusing on antibody-drug conjugates (ADCs) to address unmet medical needs [1][4] Biosimilar Pipeline - Samsung Bioepis currently has 11 biosimilars approved and launched in over 40 countries, covering 10 unique biological molecules [4] - The new biosimilar candidates include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab [4][6] - The company has launched several biosimilars, including adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), trastuzumab (Herceptin), and bevacizumab (Avastin) [3][5] Novel Therapeutics Development - SBE303 is Samsung Bioepis' first novel ADC targeting Nectin-4, with a Phase 1 clinical trial set to begin this year [4] - The company aims to introduce one novel therapeutic candidate into clinical studies each year [4] - Epis NexLab, a new subsidiary, is focused on developing a peptide-based drug delivery platform [4][9] Company Overview - Samsung Epis Holdings is dedicated to biopharmaceuticals and biotechnology, aiming to maximize corporate and shareholder value through R&D and strategic investments [7] - Samsung Bioepis, established in 2012, focuses on making healthcare accessible through innovative product development across various therapeutic areas [8] - Epis NexLab, established in 2025, is committed to driving innovation in next-generation biotechnology platforms [9]